Viscosin is a cyclic lipopeptide antibiotic produced by the bacterium Bacillus subtilis. It exhibits a wide range of biological activities, including antibacterial, antifungal, and anti-inflammatory effects. Viscosin has a unique structure consisting of a cyclic heptapeptide ring attached to a fatty acid chain. The synthesis of viscosin involves a complex biosynthetic pathway that includes non-ribosomal peptide synthesis and fatty acid modification. Research on viscosin focuses on its potential as a therapeutic agent for various diseases, including bacterial infections, fungal infections, and inflammatory conditions. Its strong antimicrobial activity, coupled with its low toxicity, makes it a promising candidate for the development of new antibiotics. Studies are ongoing to further investigate its mechanism of action, optimize its production, and explore its potential clinical applications.'
viscosin: cyclic peptide lactone with alternating D and L amino acids; found in Pseudomonas viscosa; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 72937 |
| CHEMBL ID | 4059769 |
| MeSH ID | M0173649 |
| Synonym |
|---|
| n-[n-[n-[n-[n-[n-[n-[n-[n-[(r)-3-hydroxy-1-oxodecyl]-l-leucyl]-d-.alpha.-glutamyl]-d-allothreonyl]-d-valyl]-l-leucyl]-d-seryl]-l-leucyl]-d-seryl]-l-isoleucine .upsilon.-lactone |
| 27127-62-4 |
| (4r)-5-[[(3s,6r,9s,12r,15s,18r,21r,22r)-6,12-bis(hydroxymethyl)-9,15-diisobutyl-18-isopropyl-22-methyl-3-[(1s)-1-methylpropyl]-2,5,8,11,14,17,20-heptaoxo-1-oxa-4,7,10,13,16,19-hexazacyclodocos-21-yl]amino]-4-[[(2s)-2-[[(3r)-3-hydroxydecanoyl]amino]-4-meth |
| viscosin |
| (4r)-5-[[(3s,6r,9s,12r,15s,18r,21r,22r)-3-[(2s)-butan-2-yl]-6,12-bis(hydroxymethyl)-22-methyl-9,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-18-propan-2-yl-1-oxa-4,7,10,13,16,19-hexazacyclodocos-21-yl]amino]-4-[[(2s)-2-[[(3r)-3-hydroxydecanoyl]amino] |
| 085qz2a9m9 , |
| unii-085qz2a9m9 |
| viscosin [mi] |
| l-isoleucine, n-((2r)-3-hydroxy-1-oxodecyl)-l-leucyl-d-.alpha.-glutamyl-d-allothreonyl-d-valyl-l-leucyl-d-seryl-l-leucyl-d-seryl-, (9->3)-lactone |
| DTXSID40181589 |
| CHEMBL4059769 |
| Q27236372 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The performance of these nonviral vectors appears therefore difficult to predict simply on the basis of carrier- or payload-related variables, and a more holistic consideration of the journey of the nanoparticle, from cell uptake to cytosolic bioavailability of payload, is needed." | ( Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery. Ashford, M; Gennari, A; Lallana, E; Pelliccia, M; Puri, S; Rios de la Rosa, JM; Stratford, IJ; Tirella, A; Tirelli, N, 2017) | 0.46 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1484253 | Antibiofilm activity against Candida albicans SC5314 after 48 hrs by XTT assay | 2017 | Journal of natural products, 03-24, Volume: 80, Issue:3 | Opportunistic Sampling of Roadkill as an Entry Point to Accessing Natural Products Assembled by Bacteria Associated with Non-anthropoidal Mammalian Microbiomes. |
| AID1484254 | Induction of cell killing in Candida albicans SC5314 up to 100 uM after 48 hrs by XTT assay | 2017 | Journal of natural products, 03-24, Volume: 80, Issue:3 | Opportunistic Sampling of Roadkill as an Entry Point to Accessing Natural Products Assembled by Bacteria Associated with Non-anthropoidal Mammalian Microbiomes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (47.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||